John Elder
Nephrology · Santa Barbara, CANPI 1366454225
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,155 of the $52,467 with a category attached, or 80.3%. Johnson & Johnson accounts for 92.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $46,541 and has fallen 99.9% since, to $67 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $229.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$49K
- Amgen$1K
- Novartis$436
- AstraZeneca$393
- Genentech USA, Inc.$331
- Fresenius USA Marketing, Inc.$257
- plus $1K from 17 others
Across 1 payment — averaging $7427.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$7K
What the payments were for
- Consulting fees$3751%
- Speaking & faculty fees$42,15580%
- Travel & lodging$4,9219%
- Food & beverage$4,8819%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 62 | $48,756 |
| Amgen(2 entities) | 47 | $1,122 |
| Novartis | 27 | $436 |
| AstraZeneca(2 entities) | 10 | $393 |
| Genentech USA, Inc. | 38 | $331 |
| Fresenius USA Marketing, Inc. | 2 | $257 |
| Bayer | 8 | $226 |
| Otsuka America Pharmaceutical, Inc. | 6 | $222 |
| Sanofi | 5 | $153 |
| GSK | 3 | $128 |
| AMAG Pharmaceuticals, Inc. | 4 | $85 |
| Amicus Therapeutics, Inc. | 3 | $59 |
| Lemaitre Vascular, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Sandoz | 1 | $27 |
| Pfizer | 2 | $26 |
| Bioventus LLC | 1 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,467 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 14 | $2,883 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 12 | $1,984 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Santa Barbara
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.